Keyword: Ionis Pharmaceuticals
Ionis Pharma is licensing two antisense drugs to Akcea Therapeutics, picking up a $150 million upfront fee.
The small trial linked antisense drug RG6042 to a 40% drop in levels of the mutant protein that drives the neurodegenerative disease.
Ionis could pick up $300 million in milestones and royalties as well as the $30 million licensing fee.
Perennial biotech dealmaker Takeda is at it again, striking a new pact with Wave Life Sciences with a focus on a series of neurological disorders.
AveXis is expanding trials of its gene therapy for children with spinal muscular atrophy (SMA) as it plays catch-up with Biogen and Ionis.
Ionis Pharmaceuticals has signed the rights to a second antisense drug over to Janssen for a fee of $5 million.
The gene silencing pioneer expects to complete the submission by the end of the year, setting it up to win approval in the U.S. in 2018.
Hal Barron replaces Patrick Vallance as GSK CSO, Biogen lured Merck exec to head global marketing and Celgene vet Pehl lands at Immunomedics.
Data presented by the RNAi pioneer Alnylam suggest its patisiran has the edge over Ionis’ inotersen in terms of safety and efficacy.
The data show an uptick in the proportion of patients able to sit unassisted and talk, fueling AveXis’ hopes of challenging Biogen’s Spinraza.